Repository logo
  • English
  • ไทย
Log In
New user? Click here to register. Have you forgotten your password?
Communities & Collections
All of DSpace
punsarn.menu.mahidol_journal
punsarn.menu.statistics
punsarn.menu.about.us
punsarn.menu.customer.feedback
punsarn.menu.deposit
  1. Home

Browsing by Author "Queen Sirikit National Institute of Child Health"

Filter results by typing the first few letters
Now showing 1 - 20 of 104
  • Results Per Page
  • Sort Options
  • No Thumbnail Available
    PublicationMetadata only
    Absence of platelet recovery following Helicobacter pylori eradication in childhood chronic idiopathic thrombocytopenic purpura: A multi-center randomized controlled trial
    (2009-07-15) Suporn Treepongkaruna; Nongnuch Sirachainan; Somjai Kanjanapongkul; Angkana Winaichatsak; Suebsuk Sirithorn; Rungtip Sumritsopak; Ampaiwan Chuansumrit; Mahidol University; Queen Sirikit National Institute of Child Health; Maharaj Nakhon Ratchasima Hospital; Bhumipol Adulyadej Hospital
    Objective. To investigate the effect of Helicobacter pylori eradication on platelet recovery in childhood chronic idiopathic thrombocytopenic purpura (ITP). Patients and Methods. A multicenter randomized controlled trial was conducted. Patients aged 4-18 years, diagnosed with chronic ITP, defined by platelet count below 100 × 109/L lasting more than 6 months without identified causes, were enrolled and underwent 13C-urea breath test for diagnosis of H. pylori infection. Patients who received prednisolone more than 0.5 mg/kg per day or received other platelet-enhancing therapy were excluded. Patients with H. pylori infection were randomized into two groups: treatment and control groups. Treatment group received a standard protocol for H. pylori eradication and repeated 13C-UBT at 4-6 weeks to confirm successful therapy while the control group received no specific treatment. Monthly platelet count was monitored for 6 months in both groups. Primary outcome was platelet recovery, defined by platelet count over 100 × 109/L for at least 3 months. Results. Of the 55 ITP children, 16 (29.1%) had H. pylori infection. There were no differences in age, sex, duration of disease, platelet count, and the dose of prednisolone between the treatment group (n = 7) and control group (n = 9). One patient in control group was withdrawn due to massive gastrointestinal bleeding requiring a high dose prednisolone. At 6 months, platelet recovery was demonstrated in one patient in the treatment group as well as one in the control group. Conclusion. No beneficial effect of H. pylori eradication on platelet recovery in childhood chronic ITP was identified. © 2009 Wiley-Liss, Inc.
  • No Thumbnail Available
    PublicationMetadata only
    Antimicrobial-resistant Gram-negative colonization in infants from a neonatal intensive care unit in Thailand
    (2019-10-01) T. Roberts; D. Limmathurotsakul; P. Turner; N. P.J. Day; W. P. Vandepitte; B. S. Cooper; Rangsit University; Mahidol University; Queen Sirikit National Institute of Child Health; Nuffield Department of Clinical Medicine; Mahosot Hospital; Angkor Hospital for Children
    © 2019 The Author(s) Antimicrobial-resistant Gram-negative bacteria are a major cause of morbidity and mortality in hospitalized neonates in South and South-East Asia. This study aimed to determine the dynamics of colonization with antimicrobial-resistant Gram-negative bacteria amongst patients in a neonatal intensive care unit (NICU) in Thailand. From 97 enrolled patients, 52% were colonized by an extended-spectrum β-lactamase (ESBL) organism at some point during their stay and 64% were colonized by a carbapenem-resistant organism. Rapid acquisition of ESBL-positive and carbapenem-resistant organisms was found. Once colonized with an antibiotic-resistant organism, patients remained colonized for the remainder of their NICU stay.
  • No Thumbnail Available
    PublicationMetadata only
    Assessment of bacille Calmette-Guérin vaccine reaction in HIV-exposed Thai infants
    (2007-10-22) Kulkanya Chokephaibulkit; Tawee Chotpitayasunondh; Nirun Vanprapar; Naris Waranawat; Philip A. Mock; Michelle S. McConnell; Bongkoch Jetswang; Kanchana Neeyapun; Jordan W. Tappero; Mary Culnane; Mahidol University; Queen Sirikit National Institute of Child Health; Centers for Disease Control (CDC), Thailand Field Station; Centers for Disease Control and Prevention
    We evaluated local reactions at 1, 2, and 4 months of age to bacille Calmette-Guérin vaccine given at birth to 1058 infants who were exposed to human immunodeficiency virus (HIV). No scar was discernible in 12 (12.4%) of 97 HIV-infected infants and 20 (2.1%) of 961 uninfected infants (relative risk, 5.9; 95% confidence interval, 3.0-11.8). This difference may reflect poorer immunogenicity in HIV-infected infants. © 2007 by the Infectious Diseases Society of America. All rights reserved.
  • No Thumbnail Available
    PublicationMetadata only
    Atypical oculopalatal tremor as the presentation of vertebral artery dolichoectasia
    (2016-09-06) Kavin Vanikieti; Piyaphon Cheecharoen; Panitha Jindahra; Sirin Lueangaram; Tanyatuth Padungkiatsagul; Mahidol University; Queen Sirikit National Institute of Child Health
    © 2016 Vanikieti et al. Vertebrobasilar dolichoectasia (VBD) is a rare dilative arteriopathy defined as elongation or widening of the intracranial vertebral and/or basilar arteries. The prevalence ranges from 0.06% to 5.8%. The majority of VBDs are asymptomatic. Downbeat nystagmus has been reported as a component of an infrequent ocular movement disorder in VBD. Nevertheless, oculopalatal tremor (OPT), delayed sequelae of a brainstem lesion, has never been demonstrated in VBD cases. Synchronized rhythmic involuntary contractions of the soft palate with an ocular pendular nystagmus, predominantly vertical pendular nystagmus, are the hallmark presentation. Our case demonstrated a 50-year-old female who presented with 3-month history of oscillopsia. Examination showed binocular conjugate torsional jerk nystagmus simultaneous with a contraction of the soft palate, defined as an atypical OPT, resulting from dolichoectatic left vertebral artery compressing on medulla, demonstrated by magnetic resonance imaging. Bilateral conjugate torsional jerk nystagmus simultaneous with palatal tremor, considering as an atypical OPT, should be included as one of the symptomatic presentations of vertebral artery dolichoectasia in spite of its rarity.
  • No Thumbnail Available
    PublicationMetadata only
    Cardiac CT angiography in children with congenital heart disease
    (2013-07-01) Suvipaporn Siripornpitak; Ratanaporn Pornkul; Pongsak Khowsathit; Thanarat Layangool; Worakan Promphan; Boonchob Pongpanich; Mahidol University; Queen Sirikit National Institute of Child Health
    Cardiac imaging plays an important role in both congenital and acquired heart diseases. Cardiac computed tomography (angiography) cCT(A) is a non-invasive, increasingly popular, complementary modality to echocardiography in evaluation of congenital heart diseases (CHD) in children. Despite radiation exposure, cCT(A) is now commonly used for evaluation of the complex CHD, giving information of both intra-cardiac and extra-cardiac anatomy, coronary arteries, and vascular structures. This review article will focus on the fundamentals and essentials for performing cCT(A) in children, including radiation dose awareness, basic techniques, and strengths and weaknesses of cCT(A) compared with cardiac magnetic resonance imaging (cMRI), and applications. The limitations of this modality will also be discussed, including the CHD for which cMRI may be substituted. © 2011 Elsevier Ireland Ltd.
  • No Thumbnail Available
    PublicationMetadata only
    Catch-up vaccination against Haemophilus influenzae type b in human immunodeficiency virus-infected Thai children older than 2 years old
    (2004-05-07) Kulkanya Chokephaibulkit; Wanatpreeya Phongsamart; Nirun Vanprapar; Tawee Chotpitayasunondh; Sanay Chearskul; Mahidol University; Queen Sirikit National Institute of Child Health
    Although most of Thai children older than 2 years are immune against Haemophilus influenzae type b (Hib) without prior vaccination, it may not be the case in HIV-infected children. Of 44 HIV-infected children tested before vaccination at the mean age of 36 months (range 24-84 months), 32 (73%) were susceptible (anti-PRP <0.15 μg/ml). At 6 months after a single dose of tetanus-conjugated Hib vaccination, 67% developed anti-PRP ≥0.15 μg/ml, however, only 33% developed titer of ≥1 μg/ml. Four of seven (57%) with anti-PRP 0.15-0.99 μg/ml at baseline were boosted to the titer of ≥1 μg/ml after vaccination. Seroconversion rate and geometric mean titer (GMT) level in response to the vaccination did not correlate with HIV stage, but did correlate with viral load level of 100,000 copies/ml. HIV-infected children older than 2 years would benefit from Hib vaccination, although, one dose catch-up schedule is not sufficient in a third of these children. A second dose is needed in these children especially those with viral load of level of >100,000 copies/ml. © 2003 Elsevier Ltd. All rights reserved.
  • No Thumbnail Available
    PublicationMetadata only
    Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in central Thailand, 2009-2012
    (2014-07-01) Wanatpreeya Phongsamart; Somporn Srifeungfung; Tanittha Chatsuwan; Pongpun Nunthapisud; Vipa Treerauthaweeraphong; Pimpha Rungnobhakhun; Sirintip Sricharoenchai; Kulkanya Chokephaibulkit; Mahidol University; Queen Sirikit National Institute of Child Health; Chulalongkorn University; Bhumipol Adulyadej Hospital
    © 2014 Landes Bioscience. To describe the trends in serotype distribution and antimicrobial susceptibility of S. pneumoniae causing invasive pneumococcal diseases (IPD) we tested 238 pneumococci isolates from normally sterile sites between 2009 and 2012 and compared these findings with previous data collected within our network. Serotyping was performed for 15 serotypes contained in the 7-,10-, 13-, and experimental 15-valent pneumococcal conjugate vaccines (PCV). The most common serotypes found were 6B (13.9%), 19A (12.6%), 14 (8.0%), 18C (5.9%), and 6A (3.8%); and 39.9% were non-PCV15 serotypes. One of 81 patients with available data had breakthrough infection with vaccine serotype (19F). There was a significant increase of serotype 19A among children ≤5 years (5.6% in 2000-2009 vs 18.3% in 2009-2012, P = 0.003). The all-age serotype coverage was 36.4%, 41.5%, 59.3%, and 59.7% for PCV7, PCV10, PCV13, and PCV 15, respectively. The corresponding coverage in children ≤5 years were 46.4%, 48.8%, 73.2%, and 73.2% respectively. High susceptibilities to penicillin (89.7%), cefotaxime (95.7%), cefditoren (90.2% by Spanish breakpoints), ofloxacin (97.9%), and levofloxacin (100%), but low to cefdinir (50.0%), cefditoren (45.1% by US-FDA breakpoints), macrolides (<50%), clindamycin (67.7%), tetracycline (41.4%), and trimethoprim-sulfamethoxazole (32.4%) were observed. Serotype 19A was less susceptible to penicillin (80.0 vs 91.2%, P = 0.046), cefditoren (66.7 vs 95.5% by Spanish breakpoints, P = 0.004), and tetracycline (9.1 vs 45.5%, P = 0.024) than non-19A isolates. These data emphasize the need for continued surveillance to monitor changes in serotypes as well as antimicrobial susceptibilities in order to guide strategies for prevention and treatment.
  • No Thumbnail Available
    PublicationMetadata only
    Characteristics of dengue virus-infected peripheral blood mononuclear cell death that correlates with the severity of illness
    (2009-08-01) Yanin Jaiyen; Promsin Masrinoul; Siripen Kalayanarooj; Rojjanaporn Pulmanausahakul; Sukathida Ubol; Mahidol University; Queen Sirikit National Institute of Child Health
    The pathogenic mechanism of the severe form of dengue is complicated. Recent reports indicate that apoptotic death of various tissues or organs may be associated with vascular leakage, and ultimately leads to the death of DENV-infected patients. In the present study, we provide additional evidence supporting the detrimental role of apoptosis in DENV infection. A comparison of the rate of apoptosis in PBMCs isolated from patients suffering DF, a mild form of the disease, and the rate in patients with DHF, a life-threatening disease, revealed that PBMCs from DHF patients underwent apoptosis at a significantly higher rate than those suffering from DF alone. This suggests that the severity of natural DENV infection correlates with PBMC apoptosis. In addition, this cell death was induced not only by DENV itself, but also by the apoptotic activities of pro-inflammatory cytokines, such as TNF-α, and IL-1β that were upregulated in DHF patients. The death of these mononuclear cells that function in an innate immune system may explain the higher viral load in DHF patients than in DF patients. Interestingly, a gene expression profile pattern elucidated that apoptosis occurring during natural DENV infection involved mainly the extrinsic apoptosis pathway, which is mediated via both caspase-dependent and caspase-independent mechanisms. In conclusion, our data highlight the adverse effect of apoptosis induced by DENV and by pro-inflammatory cytokines during natural DENV infection. © 2009 The Societies and Blackwell Publishing Asia Pty Ltd.
  • No Thumbnail Available
    PublicationMetadata only
    A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: Pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand
    (2010-01-01) Nirun Vanprapar; Tim R. Cressey; Kulkanya Chokephaibulkit; Petronella Muresan; Nottasorn Plipat; Virat Sirisanthana; Wasana Prasitsuebsai; Suchat Hongsiriwan; Tawee Chotpitayasunondh; Achara Eksaengsri; Maripat Toye; Mary Elizabeth Smith; Kenneth McIntosh; Edmund Capparelli; Ram Yogev; Mahidol University; Chiang Mai University; Harvard School of Public Health; University of Michigan School of Public Health; Chonburi Regional Hospital; Queen Sirikit National Institute of Child Health; Thailand Government Pharmaceutical Organization; Baystate Medical Center; National Institute of Allergy and Infectious Diseases; Children's Hospital Boston; University of California, San Diego; Ann & Robert H. Lurie Children's Hospital of Chicago
    Background: Pediatric fixed-dose combinations (FDCs) are needed to facilitate antiretroviral therapy in children. We evaluated the relative bioavailability, safety, and therapeutic adequacy of a novel chewable pediatric FDC tablet of stavudine (7 mg), lamivudine (30 mg), and nevirapine (50 mg), referred to as GPO-VIR S7, and compared it with the individual original brand-name liquid formulations in human immunodeficiency virus-infected Thai children. Methods: The International Maternal Pediatric Adolescent AIDS Clinical Trials group (IMPAACT) P1056 study was a phase I/II, 2-arm, randomized, open-label, multidose pharmacokinetic cross-over study. Children ≥6 to ≤30 kg receiving nevirapine-based HAART for at least 4 weeks were randomized to receive GPO-VIR S7 chewable tablets or the equivalent liquid formulations. Children were stratified by weight and dosing was weight-based. Intensive 12-hour blood sampling was performed on day 28, and subjects then crossed-over to the alternate formulation at equal doses with identical 12-hour sampling on day 56. Pharmacokinetic indices were determined by noncompartmental analysis. Results: Thirty-four children completed the study. While taking Government Pharmaceutical Organization (GPO)-VIR S7 the geometric mean (90% CI) area under the curve was 1.54 μg•hr/mL (1.42-1.67) for stavudine, 6.39 (5.82-7.00) for lamivudine, and 74.06 (65.62-83.60) for nevirapine. Nevirapine drug exposure for GPO-VIR S7 was therapeutically adequate. Geometric mean area under the curve ratios (90% CI) of GPO-VIR S7/liquid formulation for stavudine, lamivudine, and nevirapine were 0.97 (0.92-1.02), 1.41 (1.30-1.53), and 1.08 (1.04-1.13), respectively. No serious drug-related toxicity was reported. Conclusions: The chewable FDC was safe and provided therapeutically adequate plasma drug exposures in human immunodeficiency virus-infected children. Substituting the FDC for liquid formulations can simplify antiretroviral therapy. © 2010 by Lippincott Williams & Wilkins.
  • No Thumbnail Available
    PublicationMetadata only
    Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand
    (2019-09-11) Lukana Ngiwsara; Duangrurdee Wattanasirichaigoon; Thipwimol Tim-Aroon; Kitiwan Rojnueangnit; Saisuda Noojaroen; Arthaporn Khongkraparn; Phannee Sawangareetrakul; James R. Ketudat-Cairns; Ratana Charoenwattanasatien; Voraratt Champattanachai; Chulaluck Kuptanon; Suthipong Pangkanon; Jisnuson Svasti; Suranaree University of Technology; Chulabhorn Research Institute; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Faculty of Medicine, Thammasat University; Queen Sirikit National Institute of Child Health; Synchrotron Light Research Institute
    © 2019 The Author(s). Background: Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase (EC. 3.2.1.20) due to mutations in human GAA gene. The objective of the present study was to examine clinical and molecular characteristics of infantile-onset Pompe disease (IOPD) in Thailand. Methods: Twelve patients with infantile-onset Pompe disease (IOPD) including 10 Thai and two other Asian ethnicities were enrolled. To examine the molecular characteristics of Pompe patients, GAA gene was analyzed by PCR amplification and direct Sanger-sequencing of 20 exons coding region. The novel mutations were transiently transfected in COS-7 cells for functional verification. The severity of the mutation was rated by study of the GAA enzyme activity detected in transfected cells and culture media, as well as the quantity and quality of the proper sized GAA protein demonstrated by western blot analysis. The GAA three dimensional structures were visualized by PyMol software tool. Results: All patients had hypertrophic cardiomyopathy, generalized muscle weakness, and undetectable or < 1% of GAA normal activity. Three patients received enzyme replacement therapy with variable outcome depending on the age of the start of enzyme replacement therapy (ERT). Seventeen pathogenic mutations including four novel variants: c.876C > G (p.Tyr292X), c.1226insG (p.Asp409GlyfsX95), c.1538G > A (p.Asp513Gly), c.1895 T > G (p.Leu632Arg), and a previously reported rare allele of unknown significance: c.781G > A (p.Ala261Thr) were identified. The rating system ranked p.Tyr292X, p. Asp513Gly and p. Leu632Arg as class "B" and p. Ala261Thr as class "D" or "E". These novel mutations were located in the N-terminal beta-sheet domain and the catalytic domain. Conclusions: The present study provides useful information on the mutations of GAA gene in the underrepresented population of Asia which are more diverse than previously described and showing the hotspots in exons 14 and 5, accounting for 62% of mutant alleles. Almost all mutations identified are in class A/B. These data can benefit rapid molecular diagnosis of IOPD and severity rating of the mutations can serve as a partial substitute for cross reactive immunological material (CRIM) study.
  • No Thumbnail Available
    PublicationMetadata only
    Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial
    (2014-01-01) Maria Rosario Capeding; Ngoc Huu Tran; Sri Rezeki S. Hadinegoro; Hussain Imam Hj Muhammad Ismail; Tawee Chotpitayasunondh; Mary Noreen Chua; Chan Quang Luong; Kusnandi Rusmil; Dewa Nyoman Wirawan; Revathy Nallusamy; Punnee Pitisuttithum; Usa Thisyakorn; In Kyu Yoon; Diane Van Der Vliet; Edith Langevin; Thelma Laot; Yanee Hutagalung; Carina Frago; Mark Boaz; T. Anh Wartel; Nadia G. Tornieporth; Melanie Saville; Alain Bouckenooghe; Gokila; Pasteur Institute in Ho Chi Minh City; University of Indonesia, RSUPN Dr. Cipto Mangunkusumo; Kuala Lumpur Hospital; Queen Sirikit National Institute of Child Health; Chong Hua Hospital; Universitas Padjadjaran; Universitas Udayana; Penang Hospital; Mahidol University; Armed Forces Research Institute of Medical Sciences, Thailand; Sanofi Pasteur; Sanofi Pasteur; Sanofi Pasteur; Sanofi Pasteur; Sanofi Pasteur SA
    © © 2014 Elsevier Ltd. Background An estimated 100 million people have symptomatic dengue infection every year. This is the fi rst report of a phase 3 vaccine effi cacy trial of a candidate dengue vaccine. We aimed to assess the effi cacy of the CYD dengue vaccine against symptomatic, virologically confi rmed dengue in children.Methods We did an observer-masked, randomised controlled, multicentre, phase 3 trial in fi ve countries in the Asia- Pacifi c region. Between June 3, and Dec 1, 2011, healthy children aged 214 years were randomly assigned (2:1), by computer-generated permuted blocks of six with an interactive voice or web response system, to receive three injections of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV), or placebo, at months 0, 6, and 12. Randomisation was stratifi ed by age and site. Participants were followed up until month 25. Trial staff responsible for the preparation and administration of injections were unmasked to group allocation, but were not included in the follow-up of the participants; allocation was concealed from the study sponsor, investigators, and parents and guardians. Our primary objective was to assess protective effi cacy against symptomatic, virologically confi rmed dengue, irrespective of disease severity or serotype, that took place more than 28 days after the third injection. The primary endpoint was for the lower bound of the 95% CI of vaccine effi cacy to be greater than 25%. Analysis was by intention to treat and per procotol. This trial is registered with ClinicalTrials.gov, number NCT01373281.Findings We randomly assigned 10 275 children to receive either vaccine (n=6851) or placebo (n=3424), of whom 6710 (98%) and 3350 (98%), respectively, were included in the primary analysis. 250 cases of virologically confi rmed dengue took place more than 28 days after the third injection (117 [47%] in the vaccine group and 133 [53%] in the control group). The primary endpoint was achieved with 565% (95% CI 438664) effi cacy. We recorded 647 serious adverse events (402 [62%] in the vaccine group and 245 [38%] in the control group). 54 (1%) children in the vaccine group and 33 (1%) of those in the control group had serious adverse events that happened within 28 days of vaccination. Serious adverse events were consistent with medical disorders in this age group and were mainly infections and injuries.Interpretation Our fi ndings show that dengue vaccine is effi cacious when given as three injections at months 0, 6, and 12 to children aged 214 years in endemic areas in Asia, and has a good safety profi le. Vaccination could reduce the incidence of symptomatic infection and hospital admission and has the potential to provide an important public health benefi t.Funding Sanofi Pasteur.
  • No Thumbnail Available
    PublicationMetadata only
    Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: A prospective multicenter study
    (2019-10-16) Piya Rujkijyanont; Apichat Photia; Chanchai Traivaree; Chalinee Monsereenusorn; Usanarat Anurathapan; Panya Seksarn; Darintr Sosothikul; Piti Techavichit; Kleebsabai Sanpakit; Kamon Phuakpet; Surapon Wiangnon; Thirachit Chotsampancharoen; Su On Chainansamit; Somjai Kanjanapongkul; Arunotai Meekaewkunchorn; Suradej Hongeng; Chulalongkorn University; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Khon Kaen Regional Hospital; Faculty of Medicine, Siriraj Hospital, Mahidol University; Queen Sirikit National Institute of Child Health; Phramongkutklao College of Medicine; Prince of Songkla University; Mahasarakham University
    © 2019 The Author(s). Background: Neuroblastoma is the most common extra-cranial solid tumor among children. Despite intensive treatment, patients with advanced disease mostly experience dismal outcomes. Here, we proposed the use of topotecan and cyclophosphamide containing induction regimen as an upfront therapy to high risk neuroblastoma patients. Methods: Patients with high risk neuroblastoma undergoing ThaiPOG high risk neuroblastoma protocol from 2016 to 2017 were studied. All patients received 6 cycles of induction regimen consisting of 2 cycles topotecan (1.2 mg/m2/day) and cyclophosphamide (400 mg/m2/day) for 5 days followed by cisplatin (50 mg/m2/day) for 4 days combined with etoposide (200 mg/m2/day) for 3 days on the third and fifth cycles and cyclophosphamide (2100 mg/m2/day) for 2 days combined with doxorubicin (25 mg/m2/day) and vincristine (0.67 mg/m2/day) for 3 days on the fourth and sixth cycles. Treatment response after the 5th cycle before surgery and treatment-related toxicities after each topotecan containing induction cycle were evaluated. Relevant prognostic factors were analyzed to measure the treatment response among those patients. Results: In all, 107 high risk neuroblastoma patients were enrolled in the study. After the 5th cycle of induction regimen, the patients achieved complete response (N = 2), very good partial response (N = 40), partial response (N = 46) and mixed response (N = 19). None of the patients experienced stable disease or disease progression. The most significant prognostic factor was type of healthcare system. The most common adverse effect was febrile neutropenia followed by mucositis, diarrhea and elevated renal function. Conclusion: The topotecan and cyclophosphamide containing induction regimen effectively provides favorable treatment response. The regimen is well tolerated with minimal toxicity among patients with high risk neuroblastoma in Thailand.
  • No Thumbnail Available
    PublicationMetadata only
    A common and two novel GBA mutations in Thai patients with Gaucher disease
    (2013-09-01) Rachaneekorn Tammachote; Siraprapa Tongkobpetch; Chalurmpon Srichomthong; Kampon Phipatthanananti; Suthipong Pungkanon; Duangrurdee Wattanasirichaigoon; Kanya Suphapeetiporn; Vorasuk Shotelersuk; Chulalongkorn University; King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University; Queen Sirikit National Institute of Child Health; Mahidol University
    Gaucher disease (GD) is an autosomal recessive disorder caused by mutations in the glucocerebrosidase (GBA) gene, leading to a deficiency of lysosomal β-glucosidase and accumulation of glycosphingolipids in macrophages. We studied five Thai families with GD (four with GD type 1 and one with GD type 2). Using long-template PCR, PCR using specific primers for the functional gene, direct sequencing of all coding regions of GBA and restriction enzyme digestions, all 10 mutant alleles were successfully identified. The common c.1448T>C (p.L483P or L444P) mutation was identified in 60% of mutant alleles. Of the two patients homozygous for the p.L483P (L444P) mutation, one died from hepatic failure at age 16 years and the other died from sepsis at age 12 years. This p.L483P (L444P) mutation was found in four different haplotypes, suggesting that it was a recurrent mutation, not caused by a founder effect. Two novel mutations, a missense (c.1204T>C, p.Y402H), and a termination codon mutation (c.1609T>C, p.X537A) were found. Studies to determine the molecular pathomechanism of the p.X537A mutation, the first of its kind in this gene, showed that it decreased the amount of protein being expressed and the enzymatic activity, while it was still correctly localized. © 2013 The Japan Society of Human Genetics All rights reserved.
  • No Thumbnail Available
    PublicationMetadata only
    Comparing interferon-gamma release assays to tuberculin skin test in thai children with tuberculosis exposure
    (2014-08-14) Hong Van Tieu; Piyarat Suntarattiwong; Thanyawee Puthanakit; Tawee Chotpitayasunondh; Kulkanya Chokephaibulkit; Sunee Sirivichayakul; Supranee Buranapraditkun; Patcharawee Rungrojrat; Nitiya Chomchey; Simon Tsiouris; Scott Hammer; Vijay Nandi; Jintanat Ananworanich; New York Blood Center; Columbia University Medical Center; Queen Sirikit National Institute of Child Health; Chulalongkorn University; The HIV Netherlands Australia Thailand Research Collaboration; Mahidol University; Faculty of Medicine, Thammasat University; SEARCH; Walter Reed Army Institute of Research
    Background: Data on the performance of interferon-gamma release assays (IGRAs), QuantiFERON TB Gold In-tube (QFNGIT) and T-Spot.TB, in diagnosing tuberculosis (TB) are limited in Southeast Asia. This study aims to compare the performances of the two IGRAs and TST in Thai children with recent TB exposure. Methods: This multicenter, prospective study enrolled children with recent exposure to active TB adults. Children were investigated for active TB. TST was performed and blood collected for T-Spot.TB and QFNGIT. Results: 158 children were enrolled (87% TB-exposed and 13% active TB, mean age 7.2 years). Only 3 children had HIV infection. 66.7% had TST≥10 mm, while 38.6% had TST≥15 mm. 32.5% had positive QFNGIT; 29.9% had positive T-Spot.TB. QFNGIT and T-Spot.TB positivity was higher among children with active TB compared with TB-exposed children. No indeterminate IGRA results were detected. No statistically significant differences between the performances of the IGRAs and TST at the two cut-offs with increasing TB exposure were detected. Concordance for positive IGRAs and TST ranged from 42-46% for TST≥10 mm and 62-67% for TST≥15 mm. On multivariable analyses, exposure to household primary/secondary caregiver with TB was associated with positive QFNGIT. Higher TB contact score and active TB were associated with positive T-Spot.TB. Conclusions: Both QFNGIT and T-Spot.TB performed well in our Thai pediatric study population. No differences in the performances between tests with increasing TB exposure were found. Due to accessibility and low cost, using TST may more ideal than IGRAs in diagnosing latent and active TB in healthy children in Thailand and other similar settings. © 2014 Tieu et al.
  • No Thumbnail Available
    PublicationMetadata only
    Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection
    (2012-05-01) Stuart D. Blacksell; Richard G. Jarman; Robert V. Gibbons; Ampai Tanganuchitcharnchai; Mammen P. Mammen; Ananda Nisalak; Siripen Kalayanarooj; Mark S. Bailey; Ranjan Premaratna; H. Janaka De Silva; Nicholas P J Day; David G. Lalloog; Mahidol University; University of Oxford; Armed Forces Research Institute of Medical Sciences, Thailand; Queen Sirikit National Institute of Child Health; Royal Centre for Defence Medicine; University of Kelaniya; Liverpool School of Tropical Medicine
    Seven commercial assays were evaluated to determine their suitability for the diagnosis of acute dengue infection: (i) the Panbio dengue virus Pan-E NS1 early enzyme-linked immunosorbent assay (ELISA), second generation (Alere, Australia); (ii) the Panbio dengue virus IgM capture ELISA (Alere, Australia); (iii) the Panbio dengue virus IgG capture ELISA (Alere, Australia); (iv) the Standard Diagnostics dengue virus NS1 antigen ELISA (Standard Diagnostics, South Korea); (v) the Standard Diagnostics dengue virus IgM ELISA (Standard Diagnostics, South Korea); (vi) the Standard Diagnostics dengue virus IgG ELISA (Standard Diagnostics, South Korea); and (vii) the Platelia NS1 antigen ELISA (Bio-Rad, France). Samples from 239 Thai patients confirmed to be dengue virus positive and 98 Sri Lankan patients negative for dengue virus infection were tested. The sensitivities and specificities of the NS1 antigen ELISAs ranged from 45 to 57% and 93 to 100% and those of the IgM antibody ELISAs ranged from 85 to 89% and 88 to 100%, respectively. Combining the NS1 antigen and IgM antibody results from the Standard Diagnostics ELISAs gave the best compromise between sensitivity and specificity (87 and 96%, respectively), as well as providing the best sensitivity for patients presenting at different times after fever onset. The Panbio IgG capture ELISA correctly classified 67% of secondary dengue infection cases. This study provides strong evidence of the value of combining dengue virus antigen- and antibody-based test results in the ELISA format for the diagnosis of acute dengue infection. Copyright © 2012, American Society for Microbiology.
  • No Thumbnail Available
    PublicationMetadata only
    Comparison of the acute pulmonary vasodilating effect of beraprost sodium and nitric oxide in congenital heart disease - Thailand multicenter study
    (2005-01-01) Kritvikrom Durongpisitkul; Duangmanee Laoprasitiporn; Thanarat Layangool; Rekwan Sittiwankul; Mannat Panamonta; Pirapat Mokrapong; Mahidol University; Queen Sirikit National Institute of Child Health; Chiang Mai University; Khon Kaen University; Rajavithi Hospital
    Background: Congenital heart disease patients who have pulmonary hypertension (PH) require an evaluation for pulmonary vascular reactivity before surgical repair. In the present study the acute pulmonary vasodilating effects of 100% oxygen (O2), beraprost sodium (BPS) and 40 ppm inhaled nitric oxide (iNO) during cardiac catheterization were compared. Methods and Results: There were 90 patients who underwent cardiac catheterization for evaluation of PH (mean age, 16.5±16 years). The baseline mean pulmonary artery (mPA) pressure was 69.6±14.8 mmHg and the pulmonary arteriolar resistance (Rpa) was 13.8±8.3 Wood unit m2. Change in pulmonary vascular reactivity was defined as a decrease in mPA or Rpa >20% from baseline. The response to 100%O2, iNO and BPS during cardiac catheterization was 84%, 72.7% and 64%, respectively. Pair comparisons among each hemodynamic parameter showed no difference between the acute vasodilating effect of BPS and iNO. In some patients BPS showed a stronger effect than iNO in lowering Rpa. Conclusions: BPS has a similar pulmonary vasodilating effect to iNO and can be used as an acute pulmonary vasodilating agent during cardiac catheterization with potential benefits over iNO.
  • No Thumbnail Available
    PublicationMetadata only
    Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected with Human Immunodeficiency Virus
    (2021-08-01) Marta Massanella; Thanyawee Puthanakit; Louise Leyre; Thidarat Jupimai; Panadda Sawangsinth; Mark De Souza; Piyarat Suntarattiwong; Pope Kosalarksa; Thitiporn Borkird; Suparat Kanjanavanit; Kulkanya Chokephaibulkit; Rawiwan Hansudewechakul; Witaya Petdachai; Julie L. Mitchell; Merlin L. Robb; Lydie Trautmann; Jintanat Ananworanich; Nicolas Chomont; Siriraj Hospital; Thai Red Cross Agency; Nakornping Hospital; Faculty of Medicine, Khon Kaen University; Oregon Health & Science University; HJF; Walter Reed Army Institute of Research; Queen Sirikit National Institute of Child Health; Centre Hospitalier de L'Universite de Montreal; Faculty of Medicine, Chulalongkorn University; Bill and Melinda Gates Medical Research Institute; Hat Yai Hospital; Chiangrai Prachanukroh Hospital; Phrachomklao Hospital
    Background: Early antiretroviral therapy (ART) restricts the size of the human immunodeficiency virus (HIV) reservoir in infants. However, whether antiretroviral (ARV) prophylaxis given to exposed vertically infected children exerts similar effects remains unknown. Methods: We measured total and integrated HIV DNA, as well as the frequency of CD4 T cells producing multiply spliced RNA (msRNA) after stimulation (inducible reservoir) in vertically infected Thai infants. Eighty-five infants were followed longitudinally for up to 3 years. We compared the size of the reservoir in children who received continuous ARV prophylaxis since birth vs those who never received or discontinued prophylaxis before initiating ART. We used samples from a cross-sectional cohort of 37 Thai children who had initiated ART within 6 months of life to validate our findings. Results: Before ART, levels of HIV DNA and the frequencies of cells producing msRNA were significantly lower in infants who received continuous ARV prophylaxis since birth compared to those in whom ARV prophylaxis was discontinued or never initiated (P <. 020 and P <. 001, respectively). Upon ART initiation, total and integrated HIV DNA levels decayed significantly in both groups (P <. 01 in all cases). Interestingly, the initial differences in the frequencies of infected cells persisted during 3 years on ART. The beneficial effect of prophylaxis on the size of the HIV reservoir was confirmed in the cross-sectional study. Importantly, no differences were observed between children who discontinued prophylactic ARVs before starting ART and those who delayed ART initiation without receiving prior prophylaxis. Conclusions: Neonatal ARV prophylaxis with direct transition to ART durably limits the size of the HIV reservoir.
  • No Thumbnail Available
    PublicationMetadata only
    Correlating computed tomographic angiography of pulmonary circulation with clinical course and disease burden in patients with tetralogy of Fallot and pulmonary atresia
    (2021-01-01) Suvipaporn Siripornpitak; Uracha Kunjaru; Apichaya Sriprachyakul; Worakan Promphan; Poomiporn Katanyuwong; Ramathibodi Hospital; Queen Sirikit National Institute of Child Health
    Purpose: To determine the type of pulmonary circulation (PC) in patients with tetralogy of Fallot (TOF) and pulmonary atresia (TOF-PA) with the use of computed tomographic angiography (CTA), and describe their clinical courses, corrective surgery and disease burden. Methods: 145 patients (median age 4 years, interquartile range: IQR2-8 years) were analyzed for PC which divided into 5 CTA-types and 11 subtypes based on presence of main pulmonary trunk (MPA) and confluent pulmonary arteries (confluence-PAs), presence of ductus arteriosus or major aortopulmonary collateral arteries (MAPCAs), respectively. Pulmonary arteries (PAs) were assessed by McGoon ratio and arborization. Corrective surgery or palliative management was recorded by type of PC. Disease burden was calculated as the sum of CTA, diagnostic angiography, and palliative management. Results: The most common (N = 77, 53 %) PC was the presence of MPA with confluent-PAs (type-1) which was encountered mostly in TOF patients, followed by the presence of confluent-PAs with atretic MPA (type-2) (N = 47, 32 %) which found mainly in TOF-PA. McGoon ratio in type-1 (2.44 ± 0.84) was significantly larger than type-2 (1.61 ± 0.61) (median difference 0.84, 95 %CI 0.56–1.11, p < 0.001). Almost 2/3 of patients in type-1 (71 %) and 1/3 of patients in type-2 (34 %) achieved corrective surgery. There was no significant difference in amount of disease burden among the different PC, with the median value of 3 (IQR1-4). Conclusions: Types of PC allow suggestions for size and arborization of PAs and successful surgical correction with an inverse relationship with the numbers of MAPCAs. There is no significant difference in amount of disease burden among the types of PC.
  • No Thumbnail Available
    PublicationMetadata only
    Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context?
    (2013-06-10) Wantanee Kulpeng; Pattara Leelahavarong; Waranya Rattanavipapong; Vorasith Sornsrivichai; Henry C. Baggett; Aronrag Meeyai; Warunee Punpanich; Yot Teerawattananon; Thailand Ministry of Public Health; Prince of Songkla University; Mahidol University; Queen Sirikit National Institute of Child Health
    Objective: This study aims to evaluate the costs and outcomes of offering the 10-valent pneumococcal conjugate vaccine (PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13) in Thailand compared to the current situation of no PCV vaccination. Methods: Two vaccination schedules were considered: two-dose primary series plus a booster dose (2. +. 1) and three-dose primary series plus a booster dose (3. +. 1). A cost-utility analysis was conducted using a societal perspective. A Markov simulation model was used to estimate the relevant costs and health outcomes for a lifetime horizon. Costs were collected and values were calculated for the year 2010. The results were reported as incremental cost-effectiveness ratios (ICERs) in Thai Baht (THB) per quality adjusted life year (QALY) gained, with future costs and outcomes being discounted at 3% per annum. One-way sensitivity analysis and probabilistic sensitivity analysis using a Monte Carlo simulation were performed to assess parameter uncertainty. Results: Under the base case-scenario of 2. +. 1 dose schedule and a five-year protection, without indirect vaccine effects, the ICER for PCV10 and PCV13 were THB 1,368,072 and THB 1,490,305 per QALY gained, respectively. With indirect vaccine effects, the ICER of PCV10 was THB 519,399, and for PCV13 was THB 527,378. The model was sensitive to discount rate, the change in duration of vaccine protection and the incidence of pneumonia for all age groups. Conclusions: At current prices, PCV10 and PCV13 are not cost-effective in Thailand. Inclusion of indirect vaccine effects substantially reduced the ICERs for both vaccines, but did not result in cost effectiveness. © 2013 Elsevier Ltd.
  • No Thumbnail Available
    PublicationMetadata only
    Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand
    (2020-09-15) Nitichen Kittiratchakool; Disorn Kulpokin; Chonticha Chanjam; Soamarat Vilaiyuk; Sirirat Charuvanij; Gun Phongsamart; Parichat Khaosut; Manasita Tanya; Ratanavadee Nanagara; Sira Nantapaisarn; Pattara Leelahavarong; Chulalongkorn University; Khon Kaen University; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Khon Kaen Regional Hospital; Thammasat University; Faculty of Medicine, Siriraj Hospital, Mahidol University; Queen Sirikit National Institute of Child Health; Health Intervention and Technology Assessment Program
    © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. OBJECTIVES: This study aimed to analyse the cost-utility and budget impact of adding tocilizumab to the standard treatment for patients with refractory systemic juvenile idiopathic arthritis (sJIA) in Thailand. DESIGN: Economic evaluation using a decision-analytical model.Thailand. PARTICIPANTS: Patients with refractory sJIA who were ≥2 years old. METHODS: The use of tocilizumab as an add-on therapy to standard treatment was compared with standard treatment alone. A simulated health state transition model was used to estimate the lifetime costs and health outcomes from a societal perspective. Direct medical costs were collected from tertiary hospital databases while direct non-medical costs were derived from interviews. Health-related quality of life (QoL) was measured using the proxy version of three-level EuroQol five-dimensional questionnaire (EQ-5D-3L). Future costs and outcomes were discounted at an annual rate of 3%. The base case population was patients aged 9.41 years old at refractory disease onset. The results were reported as incremental cost-effectiveness ratios (ICER) in US dollar (USD). One-way and probabilistic sensitivity analysis were conducted to investigate parameter uncertainty. The 5-year budget impact was estimated from a governmental perspective. RESULTS: The ICER of standard treatment plus tocilizumab was US$35 799 per quality-adjusted life-year (QALY) gained compared with standard treatment alone, which was not cost-effective at the threshold of US$5128 per QALY gained. The estimated 5 years budget impact was approximately US$4.8 million. CONCLUSIONS: The use of standard treatment plus tocilizumab was not cost-effective in the Thai context, which has limited data. However, there is currently no second-line treatment for refractory sJIA in the Thai National List of Essential Medicines; thus, patients must receive higher doses of standard treatment which can cause many side effects. In contrast, tocilizumab showed obvious efficacy in clinical trials in improving treatment response and QoL. Therefore, the price of tocilizumab should be negotiated to reduce the financial impact on the healthcare system.
  • «
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • »
footer.content.left
Certified Logo

มตช./ข้อกำหนดเผยแพร่ 2001-2567 คลังสารสนเทศดิจิทัล - ข้อกำหนด

TCAS/TPAS 2001:2024 DIGITAL REPOSITORIES - REQUIREMENTS

  • Privacy policy
  • End User Agreement